Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Liabilities from Discontinued Operations (2016)

Protalix BioTherapeutics has reported Liabilities from Discontinued Operations over the past 3 years, most recently at 293000.0 for Q2 2016.

  • Quarterly results put Liabilities from Discontinued Operations at 293000.0 for Q2 2016, changed N/A from a year ago — trailing twelve months through Jun 2016 was 293000.0 (changed N/A YoY), and the annual figure for FY2015 was 1568000.0, down 97.03%.
  • Liabilities from Discontinued Operations for Q2 2016 was 293000.0 at Protalix BioTherapeutics, up from 128000.0 in the prior quarter.
  • Over the last five years, Liabilities from Discontinued Operations for PLX hit a ceiling of 52830000.0 in Q4 2014 and a floor of 128000.0 in Q1 2016.
  • Median Liabilities from Discontinued Operations over the past 3 years was 930500.0 (2015), compared with a mean of 13704750.0.
  • Peak annual rise in Liabilities from Discontinued Operations hit 97.03% in 2015, while the deepest fall reached 97.03% in 2015.
  • Protalix BioTherapeutics' Liabilities from Discontinued Operations stood at 52830000.0 in 2014, then tumbled by 97.03% to 1568000.0 in 2015, then crashed by 81.31% to 293000.0 in 2016.
  • The last three reported values for Liabilities from Discontinued Operations were 293000.0 (Q2 2016), 128000.0 (Q1 2016), and 1568000.0 (Q4 2015) per Business Quant data.